Originally published as JCO Early Release 10.1200/JCO.2009.23.5481 on September 14 2009
Journal of Clinical Oncology, Vol 27, No 29 (October 10), 2009: pp. 4885-4888
© 2009 American Society of Clinical Oncology.
Prevention of Thrombosis in Ambulatory Patients With Cancer
Punam Rana,
Mark N. Levine
From the Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada.
Corresponding author: Mark N. Levine, MD MSc, Henderson Research Centre, 711 Concession St, Hamilton, Ontario, Canada L8V 1C3; email: mlevine{at}mcmaster.ca.
Cancer patients with solid tumors or hematologic malignancies receive most of their cancer treatment as outpatients. Thromboembolism, when it occurs, complicates the clinical care of these patients because of the associated morbidity and the need for anticoagulant treatment. It would seem that prevention of venous thromboembolism in these patients would be worthwhile. However, to date there are relatively few trials of anticoagulant prophylaxis in ambulatory patients with cancer and it is not possible to recommend prophylaxis for most patients. Research is needed to better define a population at high enough risk to warrant pharmacologic prophylaxis and to develop new antithrombotic agents for this indication.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. H. Lyman and A. A. Khorana
Cancer, Clots and Consensus: New Understanding of an Old Problem
J. Clin. Oncol.,
October 10, 2009;
27(29):
4821 - 4826.
[Full Text]
[PDF]
|
 |
|
|